title: Suppression of basophil FcɛRI activation by serum from active chronic idiopathic/spontaneous urticaria (CIU/CSU) subjects.
authors.affiliation: Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Sterba
authors.affiliation: Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Robert G
authors.initials: RG
authors.lastname: Hamilton
authors.affiliation: Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: ssaini@jhmi.edu.
authors.forename: Sarbjit S
authors.initials: SS
authors.lastname: Saini
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001491:Basophils / Q000166:cytology / Q000378:metabolism*; D002478:Cells, Cultured; D002908:Chronic Disease; D003165:Complement System Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D000069444:Omalizumab; D017455:Receptors, IgE / Q000378:metabolism*; D044967:Serum / Q000502:physiology*; D014581:Urticaria / Q000097:blood* / Q000188:drug therapy
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D017455:Receptors, IgE; D000069444:Omalizumab; D007073:Immunoglobulin E; D003165:Complement System Proteins